

Match Overview

| | | |
|---|---|-----|
| 1 | Crossref 41 words Erin K. Spengler, Rohit Loomba, "Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalco... | 1% |
| 2 | Internet 24 words crawled on 18-Oct-2020 en.wikipedia.org | 1% |
| 3 | Internet 22 words crawled on 17-Mar-2020 www.researchsquare.com | 1% |
| 4 | Internet 13 words crawled on 04-Nov-2020 oncologypro.esmo.org | <1% |
| 5 | Internet 13 words crawled on 04-Oct-2020 eglj.springeropen.com | <1% |
| 6 | Internet 12 words crawled on 13-Jul-2020 medpol.providers.amerigroup.com | <1% |

Name of Journal: *World Journal of Hepatology*

Manuscript NO: 61090

Manuscript Type: EVIDENCE-BASED MEDICINE

Awareness of NASH and treatment guidelines: What are physicians telling us?

Awareness of NASH and treatment guidelines: What are physicians telling us?

David Hermanus Wessels, Zeil Rosenberg

激活 Windows
转到“设置”以激活 Windows。



Awareness of NASH and treatment guidelines: What are physicians



Sign in



ALL

IMAGES

VIDEOS

11,500,000 Results

Any time ▾

Awareness of nonalcoholic steatohepatitis and associated ...

<https://bmcrenotes.biomedcentral.com/articles/10.1186/s13104-016-1946-1> ▾

Mar 11, 2016 · In addition, 53 % of **physicians** mentioned prescribing vitamin E for **NASH treatment** , even though the guideline indicates it should not be used without a liver biopsy , and 50 % mentioned prescribing metformin for some patients specifically to treat **NASH** while the **guidelines** do not recommend its use for treating **NASH** .

Cited by: 13

Author: Susan Polanco-Briceno, Daniel Glass, Mark...

Publish Year: 2016

Search Tools

Turn on Hover Translation (开启取词)

NASH AWARE | NASH AWARE: Raising awareness for NASH, the ...

<https://nashaware.com> ▾

Today the FDA announced that it had declined to approve Ocaliva for **treatment of NASH**. Intercept Pharmaceuticals was set to be the first FDA approved **NASH treatment**, despite relatively mediocre Phase 3 Results announced in late 2019. This is a major disappointment for the tens of millions of **NASH** patients that were hoping for an imminent **treatment** to be available.

[Diagnosing](#) · [Obesity](#) · [Intercept](#) · [Fructose](#) · [Stigma](#) · [Insulin](#)

Clinical Consultations™: Targeting NASH: Expert ...

激活 Windows

转到“设置”以激活 Windows。

ALL

IMAGES

VIDEOS

10,400,000 Results

Any time ▾

[Awareness of nonalcoholic steatohepatitis and associated ...](#)

<https://bmccresnotes.biomedcentral.com/articles/10.1186/s13104-016-1946-1> ▾

Mar 11, 2016 · In addition, 53 % of **physicians** mentioned prescribing vitamin E for **NASH treatment** , even though the guideline indicates it should not be used without a liver biopsy , and 50 % mentioned prescribing metformin for some patients specifically to treat **NASH** while the **guidelines** do not recommend its use for treating **NASH** .

Cited by: 14

Author: Susan Polanco-Briceno, Daniel Glass, Mark...

Publish Year: 2016

[Clinical Consultations™: Targeting NASH: Expert ...](#)

<https://learning.freecme.com/a/33722PA9qVbX> ▾

Nov 13, 2019 · Fueled by the obesity epidemic and increasing prevalence of type 2 diabetes, **NASH** is considered the hepatic expression of metabolic syndrome. Because of low **awareness** of patients at risk of disease progression, the development of **NASH** is frequently not detected until cirrhosis is established. Current **treatment** consists of lifestyle interventions.

Search Tools

[Turn off Hover Translation \(关闭取词\)](#)

PEOPLE ALSO ASK

What are the signs of Nash?



[ALL](#)[IMAGES](#)[VIDEOS](#)[MAPS](#)[NEWS](#)[SHOPPING](#)

56,800 Results

Any time ▾

[Awareness of nonalcoholic steatohepatitis and associated ...](#)

<https://bmcrenotes.biomedcentral.com/articles/10.1186/s13104-016-1946-1>

Mar 11, 2016 · Patients with nonalcoholic steatohepatitis, the progressive form of nonalcoholic fatty liver disease, have **increased risk of fibrosis, cirrhosis and end-stage liver disease**. Estimates of prevalence in the United States range from 20–30 % for nonalcoholic fatty liver disease and 2–5 % for nonalcoholic steatohepatitis; however, physician awareness of these diseases is limited.

Cited by: 14**Author:** Susan Polanco-Briceno, Daniel Glass, Mark...**Publish Year:** 2016

[Awareness of nonalcoholic steatohepatitis and associated ...](#)

<https://www.europepmc.org/articles/PMC4788895>

Mar 11, 2016 · The purpose of this study was to determine the **current level of physician awareness and practices in the diagnosis and management of nonalcoholic fatty liver disease** and nonalcoholic steatohepatitis within the United States. Physicians were asked to participate in an online, 35-question survey about their awareness of various liver conditions and current practices. Of the 302 responding ...

Cited by: 14**Author:** Susan Polanco-Briceno, Daniel Glass, Mark...**Publish Year:** 2016

[Knowing What's Out There: Awareness of Non-Alcoholic Fatty ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351614>

Mar 24, 2014 · Background: Non-alcoholic fatty liver disease (NAFLD) is the most common hepatic disorder, which poses a significant health burden in the western countries. As the epidemic of obesity slides health downward, the incidence of NAFLD is evidently increasing. Aim: We aimed to ascertain the **awareness** of NAFLD and its risk factors in the general population, which may be helpful in designing ...

Cited by: 13**Author:** Vishal Ghevariya, Nan Sandar, Kishor Patel,...**Publish Year:** 2014

[Awareness of nonalcoholic steatohepatitis and associated ...](#)